# Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer

> **NCT01264328** · PHASE2 · COMPLETED · sponsor: **Grupo Español de Tratamiento de Tumores de Cabeza y Cuello** · enrollment: 40 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Panitumumab + paclitaxel

## Key facts

- **NCT ID:** NCT01264328
- **Lead sponsor:** Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-09
- **Primary completion:** 2011-10
- **Final completion:** 2014-09-29
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01264328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01264328, "Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01264328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*